<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955461</url>
  </required_header>
  <id_info>
    <org_study_id>C66-07-F</org_study_id>
    <nct_id>NCT00955461</nct_id>
  </id_info>
  <brief_title>Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System</brief_title>
  <official_title>Post-Market, Randomized, Single Blind, Split-Faced Comparison of the RevLite Nd:YAG Laser System Versus a Non-Ablative, Mid Infra-red, Fractionated Type Laser System for Skin Rejuvenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ConBio, a Cynosure Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the results of treatment between the side of the face
      treated with the RevLite Laser and the side of the face treated with a fractionated laser
      system.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the percentage of overall, cumulative improvement from Baseline in the appearance of wrinkles, skin tone and/or texture, pigmentation and acne scars</measure>
    <time_frame>3 and 6 months post final treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Photodamage</condition>
  <condition>Irregular Pigmentation</condition>
  <condition>Acne Scars</condition>
  <arm_group>
    <arm_group_label>Laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Split-Face Comparison of an Electro-optic Q-Switched Nd: YAG Laser to a Fractionated Laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RevLite laser treatment</intervention_name>
    <description>Electro-optic Q-Switched Nd: YAG Laser treatment</description>
    <arm_group_label>Laser treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fractionated Laser treatment</intervention_name>
    <arm_group_label>Laser treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fitzpatrick Skin Type I-VI and Wrinkle Class I

          -  Between the ages of 25-65

          -  Evidence of bilateral dyschromia

        Exclusion Criteria:

          -  Pregnant, lactating, or is planning to become pregnant

          -  history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or
             photodermatosis

          -  any skin pathology/condition that could interfere with evaluation or requires the use
             of interfering topical or systemic therapy

          -  coagulation disorder or currently using anti-coagulation medication (including but not
             limited to heavy aspirin therapy)

          -  any condition which, in the investigator's opinion, would make it unsafe for the
             subject to participate in the study

          -  currently enrolled in an investigational drug or device trial, or has received an
             investigational drug or been treated with an investigational device within 30 days

          -  unable to communicate or cooperate with the investigator due to language problems,
             poor mental development, or impaired cerebral function

          -  unreliable for the study, including subjects who engage in excessive alcohol intake or
             drug abuse, or subjects who are unable to return for scheduled follow-up visits

          -  Accutane within 6 months

          -  need to be exposed to artificial tanning devices or excessive sunlight during the
             trial

          -  prior treatment with parenteral gold therapy

          -  Diabetes Type 1 or 2

          -  does not agree to refrain from any other type of facial skin resurfacing (e.g.,
             microdermabrasion, laser or IPL treatment, chemical peel) or injected fillers/other
             substances (e.g., Restylane, Botox) that might affect the treatment area for the
             duration of the study

          -  artificial tanning within 1 month

          -  (micro)dermabrasion within 3 months

          -  other laser or IPL to the face within 6 months

          -  chemical peel within 1 month

          -  injectable fillers within 3 months

          -  topical retinoids within 3 months

          -  over-the-counter anti-aging products (e.g., those containing peptides, hyaluronic
             acid, or agents specifically advertised as having anti-aging or age-inhibiting
             properties) within 1 month

          -  history of keloids or hypertrophic scarring

          -  evidence of compromised wound healing

          -  history of cold sores, chickenpox or shingles and unwilling to take a prophylactic
             course of Valtrex/acyclovir

          -  allergy to acyclovir
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Sadick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sadick Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sadick Research Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

